Physician profile
William M Silverman
NPI 1083619639
$18,627.02
in general payments reported to CMS, 2019-2025
63 companies · $1,622 in 2025
The $1,622 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,564 · 2020: $3,371 · 2021: $3,247 · 2022: $2,623 · 2023: $2,438 · 2024: $1,762 · 2025: $1,622.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,784 · Education: $38.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,783.52 |
| Education | $38.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,493.57 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $1,429.66 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,036.73 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $1,029.21 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $984.23 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Sanofi-Aventis U.S. LLC | $896.60 | 2019-2023 | |
| Amgen INC. | $888.15 | 2019-2025 | Repatha, Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $767.72 | 2019-2025 | Xifaxan, Relistor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $695.90 | 2019-2024 | Jardiance, Tradjenta, Synjardy |
| Pfizer INC. | $655.62 | 2019-2025 | |
| Amarin Pharma, INC. | $589.04 | 2019-2023 | |
| Otsuka America Pharmaceutical, INC. | $542.60 | 2021-2025 | Rexulti, Nuedexta |
| Astellas Pharma US INC | $538.64 | 2019-2025 | Veozah, Myrbetriq |
| Radius Health, INC. | $506.35 | 2019-2025 | |
| Allergan, INC. | $451.31 | 2019-2021 |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Silverman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.